Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY3200882 |
Synonyms | |
Therapy Description |
LY3200882 is a small molecule that inhibits TGFBR1, potentially resulting in increased anti-tumor immune response and decreased tumor growth (AACR Annual Meeting 2017, Abstract nr 955). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY3200882 | LY 3200882 | TGFBR1 inhibitor 16 | LY3200882 is a small molecule that inhibits TGFBR1, potentially resulting in increased anti-tumor immune response and decreased tumor growth (AACR Annual Meeting 2017, Abstract nr 955). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02937272 | Phase I | LY3200882 | A Study of LY3200882 in Participants With Solid Tumors | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUS | 1 |